Clinical Trials Logo

Clinical Trial Summary

Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.

Clinical Trial Description

Bipolar disorder is a common and disabling condition with a high rate of suicide. The depressed phase of the disorder accounts for most of the morbidity and mortality. Only four medications are FDA approved to treat bipolar depression. They all include a second generation antipsychotic (SGA), yet the antidepressant mechanism of SGA's is unknown. Not all bipolar patients respond to these treatments, and they can have problematic side effects. There is therefore a great need to understand these medications' antidepressant mechanism of action in order to design more effective treatment options. We propose an exploratory occupancy study with cariprazine (Vraylar) in unmedicated participants with bipolar depression (n=8). Participants will have [11C]-(+)-PHNO scans before treatment starts, after three weeks of cariprazine, and after six weeks. Participants will be randomized to two dose groups, 1.5 mg daily (n=4) and 3 mg daily (n=4). These are typical doses of the medication for bipolar depression. Serum levels of cariprazine will be measured at each PET scan. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05060549
Study type Interventional
Source New York State Psychiatric Institute
Contact Martin Lan, MD
Phone 646 774 7610
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date December 1, 2021
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Recruiting NCT03396744 - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression Phase 1/Phase 2
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Completed NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Terminated NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Recruiting NCT04998773 - Efficacy of TBS in Treatment Resistant Depression N/A
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Completed NCT03658824 - Behavioural Activation for Bipolar Depression: A Case Series N/A
Recruiting NCT03674671 - Ketamine Versus Electroconvulsive Therapy in Depression Phase 3
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1
Completed NCT00566150 - Levetiracetam in the Management of Bipolar Depression N/A
Completed NCT04420793 - Voice Changes During ECT